As part of the refi Fridley, Minn.-based Medtronic put up $7.77 billion in a tender offer it launched last month for a set of senior notes due 2020 and another set due between 2037 and 2043.
Today the world’s largest medical device maker said the closing of the new $7.0 billion notes offering triggered the tender offer redemption of $2.1 billion of the 2020 notes and another $3.8 billion in the second set of notes. That $5.9 billion nut will be covered by the $7.77 billion in net proceeds from the new flotation, the company said, adding that it plans to use the overflow to redeem $700 million in 2.5% senior notes due 2020 and $200 million in 4.2% senior notes due 2020 and a set of 1.7% notes due to mature March 28.
The new offering contained €500 million in floating rate senior notes due 2021, €1.50 billion in 0.0% senior notes due 2021, €1.50 billion in 0.375% senior notes due 2023, €1.50 billion in 1.125% senior notes due 2027, €1.0 billion in 1.625% senior notes due 2031 and €1.0 billion in 2.250% senior notes due 2039, the company said.
Barclays Bank and Merrill Lynch were joint book-runners for the offering; Barclays Capital and BofA Merrill Lynch were the dealer managers for the tender, with Global Bondholder Services as information & tender agent.
($1 = €0.888237)
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.